NAVIDEA BIOPHARMACEUTICALS I's ticker is NAVB and the CUSIP is 63937X202. A total of 26 filers reported holding NAVIDEA BIOPHARMACEUTICALS I in Q1 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $33,084 | +256.1% | 368,830 | +265.2% | 0.00% | – |
Q2 2023 | $9,291 | -65.8% | 100,998 | -3.5% | 0.00% | – |
Q1 2023 | $27,200 | +129423.8% | 104,619 | 0.0% | 0.00% | – |
Q4 2022 | $21 | -99.9% | 104,619 | 0.0% | 0.00% | – |
Q3 2022 | $26,000 | -65.3% | 104,619 | 0.0% | 0.00% | – |
Q2 2022 | $75,000 | -1.3% | 104,619 | +7.6% | 0.00% | – |
Q1 2022 | $76,000 | -21.6% | 97,206 | 0.0% | 0.00% | – |
Q4 2021 | $97,000 | -42.9% | 97,206 | 0.0% | 0.00% | – |
Q3 2021 | $170,000 | -4.0% | 97,206 | 0.0% | 0.00% | – |
Q2 2021 | $177,000 | +17.2% | 97,206 | +29.4% | 0.00% | – |
Q1 2021 | $151,000 | -6.2% | 75,142 | 0.0% | 0.00% | – |
Q4 2020 | $161,000 | -20.3% | 75,142 | 0.0% | 0.00% | – |
Q3 2020 | $202,000 | +32.0% | 75,142 | +92.8% | 0.00% | – |
Q2 2020 | $153,000 | +466.7% | 38,979 | +8.2% | 0.00% | – |
Q1 2020 | $27,000 | -70.0% | 36,009 | -50.0% | 0.00% | – |
Q4 2019 | $90,000 | +275.0% | 72,018 | +100.0% | 0.00% | – |
Q3 2019 | $24,000 | +9.1% | 36,009 | 0.0% | 0.00% | – |
Q2 2019 | $22,000 | – | 36,009 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Allred Capital Management, LLC | 52,926 | $113,000 | 0.06% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 109,940 | $236,000 | 0.01% |
PATHSTONE FAMILY OFFICE, LLC | 10,050 | $22,000 | 0.00% |
Sowell Financial Services LLC | 11,190 | $24,000 | 0.00% |
TWO SIGMA INVESTMENTS, LP | 101,949 | $219,000 | 0.00% |
SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC | 32,822 | $71,000 | 0.00% |
UBS Group AG | 816 | $2,000 | 0.00% |
IFP Advisors, Inc | 50 | $0 | 0.00% |
OSAIC HOLDINGS, INC. | 6 | $0 | 0.00% |
Jacobi Capital Management LLC | 1,000 | $2,000 | 0.00% |